Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma

This study demonstrates that Daraxonrasib (RMC-6236), a potent RAS(ON) inhibitor, effectively suppresses tumor growth and induces cell death in RAS-mutant neuroblastoma models by inhibiting MAPK signaling and upregulating BIM, with its efficacy further enhanced when combined with the BCL-2 inhibitor venetoclax, thereby supporting its clinical development for this high-risk patient subset.

The Gist

The Big Picture: A Broken Engine in a Child's Cancer

Imagine Neuroblastoma as a very aggressive, stubborn car that refuses to stop moving. It is the most common solid tumor in young children. While doctors have many tools to fix "standard" cars (low-risk tumors), the "high-risk" versions are like cars with a broken engine that keeps revving even when the driver takes their foot off the gas.

For a long time, the most dangerous version of this cancer has been driven by a specific problem: a broken RAS engine. This engine is stuck in the "ON" position, telling the cancer cells to grow, divide, and survive endlessly.

The Problem: The Old Keys Didn't Fit

Scientists tried to fix this broken engine using standard keys (drugs):

1. MEK Inhibitors: These were like trying to jam a wrench into the gears. They worked a little bit, but the cancer quickly learned to bypass the wrench and keep running.
2. KRAS G12C Inhibitors: These were like a key that only fits one specific type of lock. But in neuroblastoma, the "locks" (mutations) are all different types. So, the key didn't fit most of the cars.

The result? The high-risk cancer kept winning, and the children's survival rates remained low.

The New Solution: The "Master Key" (Daraxonrasib / RMC-6236)

Enter the hero of this story: Daraxonrasib (RMC-6236).

Think of the RAS protein as a light switch that is stuck in the "ON" position.

• Old drugs tried to break the lightbulb or cut the wire, but the cancer found a way around it.
• Daraxonrasib is a "Master Key" or a smart clamp. It doesn't matter what kind of switch is broken (whether it's a KRAS, NRAS, or HRAS mutation, or even if the safety switch NF1 is missing). This drug clamps down on the switch while it is in the ON position, forcing it to stay OFF.

What happened in the lab?
When the researchers gave this "smart clamp" to the cancer cells:

• The engine stopped revving.
• The cancer cells realized they couldn't survive without the signal, so they started to self-destruct (a process called apoptosis).
• It worked on cells with broken switches and cells where the safety mechanism was missing.

The "Double-Whammy" Strategy

Here is where the science gets really clever.

When the "smart clamp" (Daraxonrasib) turns off the engine, the cancer cells panic. To survive, they try to build a shield (a protein called BCL-2) to protect themselves from dying. However, in doing so, they accidentally create a trap.

Inside this shield, they trap a "suicide signal" (a protein called BIM). The shield is holding the suicide signal hostage, preventing it from killing the cell.

The Second Drug: Venetoclax
The researchers realized that if they added a second drug, Venetoclax (which is already approved for blood cancers), it acts like a lockpick.

• Step 1: Daraxonrasib turns off the engine and forces the cell to build the shield, trapping the suicide signal inside.
• Step 2: Venetoclax picks the lock of the shield, releasing the suicide signal.
• Result: The cancer cell is overwhelmed. It can't survive without the engine, and now its own shield has been turned against it.

Analogy: Imagine a prisoner (the cancer cell) is locked in a room.

1. Daraxonrasib turns off the lights and locks the door, making the prisoner desperate.
2. The prisoner builds a wall to hide a bomb (the suicide signal) inside the room.
3. Venetoclax is a sledgehammer that smashes the wall, releasing the bomb right next to the prisoner.

• Result: The prisoner is gone.

The Results: Real-World Success

The researchers tested this in two ways:

1. In a Petri Dish: The drug killed the cancer cells effectively, even at very low doses, while leaving normal, healthy cells alone.
2. In Mice: They gave the drug to mice with human neuroblastoma tumors.
   • Tumor Growth: The tumors shrank or stopped growing completely.
   • Survival: The mice treated with the drug lived much longer than those who didn't get it. In some cases, the mice treated with the drug were still alive weeks after the untreated mice had to be put down because their tumors were too big.

Why This Matters

This paper is a beacon of hope for a specific group of children with neuroblastoma who currently have very few options.

• It proves that targeting the "RAS engine" directly works better than the old methods.
• It shows that combining this new drug with an existing drug (Venetoclax) creates a powerful one-two punch that the cancer cannot escape.

The Bottom Line:
The researchers have found a new "Master Key" that fits the broken engines of the most dangerous neuroblastoma tumors. By using this key alone, or better yet, using it to set a trap for a second drug, they have shown a way to stop the cancer in its tracks. This paves the way for clinical trials to test if this works in children, offering a potential new lifeline for families facing this difficult disease.

Technical Summary

1. Problem Statement

Neuroblastoma (NB) is the most common extracranial solid tumor in children, with high-risk (HR) and relapsed/refractory (R/R) cases exhibiting poor survival rates (<50% 5-year survival). A significant subset of these aggressive tumors harbors activating mutations in the RAS-MAPK pathway (including KRAS, NRAS, HRAS, and NF1 loss-of-function).

• Current Limitations: Despite the clear role of the MAPK pathway, previous targeted therapies have failed:
  • MEK inhibitors (e.g., trametinib) show limited efficacy due to adaptive resistance, feedback activation of alternative pathways (PI3K/AKT/mTOR), and a narrow therapeutic window (toxicity to normal tissues).
  • KRAS G12C inhibitors are ineffective because NB tumors often harbor diverse RAS mutations (not just G12C) and rely heavily on wild-type NRAS.
  • SHP2 inhibitors are largely ineffective in RAS-mutant cancers where active RAS bypasses the need for SHP2.
• The Gap: There is an urgent need for a potent, selective inhibitor capable of targeting diverse RAS mutations and wild-type NRAS in NB with a favorable therapeutic window.

2. Methodology

The study utilized a comprehensive preclinical approach involving in vitro and in vivo models:

• Cell Lines: A panel of NB cell lines was used, including:
  • RAS-mutant: CHP-212 (NRAS Q61K), NB-EBc1 (KRAS G12D), SK-N-AS (NRAS Q61K), LAN6 (KRAS G12C).
  • NF1-altered: SK-N-FI (NF1 homozygous deletion), MHH-NB-11 (NF1 wild-type but profoundly low expression).
  • Controls: IMR5 (RAS/NF1 wild-type, MYCN amplified) and normal tissue-derived lines (AC16, MRC5, RPE.1, HCE-T).
• Drug: Daraxonrasib (RMC-6236), a next-generation, non-covalent, pan-RAS(ON) inhibitor that allosterically binds activated RAS to prevent RAF dimerization.
• Assays:
  • Viability: Crystal Violet and CellTiter-Glo assays to measure dose-dependent cytotoxicity.
  • 3D Models: Spheroid formation assays to assess anti-tumor activity in a more physiological context.
  • Mechanistic Studies: Western blotting for MAPK pathway markers (p-ERK, p-S6), apoptosis markers (cleaved PARP, cleaved Caspase 3), and BCL-2 family proteins (BIM, BCL-2, MCL-1, BCL-xL).
  • Combination Therapy: Synergy testing with Venetoclax (BCL-2 inhibitor) using Bliss independence scoring.
  • Genetic Manipulation: siRNA knockdown of BIM to validate its role in drug-induced apoptosis.
  • In Vivo Models: Bilateral flank xenografts in NSG mice using NB-EBc1 (KRAS G12D) and SK-N-AS (NRAS Q61K) cell lines. Treated with 25 mg/kg RMC-6236 via oral gavage (5 days on/2 days off) for 4 weeks.
  • Analysis: Tumor volume measurement, survival analysis (Kaplan-Meier), Ki67 immunohistochemistry (IHC), and tumor lysate Western blotting.

3. Key Contributions

• Validation of RMC-6236 in Pediatric Cancer: This is the first study to demonstrate the efficacy of RMC-6236 specifically in RAS-mutant and NF1-deficient neuroblastoma models.
• Mechanistic Insight into Combination Therapy: The study elucidates a novel mechanism where RMC-6236 "primes" tumor cells for Venetoclax by upregulating BIM and BCL-2, thereby increasing the formation of BIM:BCL-2 complexes.
• Therapeutic Window Demonstration: The study confirms that RMC-6236 selectively targets RAS/NF1-altered cells while sparing normal tissue-derived cells, addressing the toxicity issues seen with MEK inhibitors.
• Broad Applicability: Demonstrated efficacy across diverse RAS mutations (KRAS, NRAS) and NF1 loss-of-function (both deletion and epigenetic silencing), covering a broader patient population than isoform-specific inhibitors.

4. Key Results

• Selective Cytotoxicity: RMC-6236 induced a dose-dependent decrease in cell viability in all RAS-mutant and NF1-altered NB models (IC50 in the low nanomolar range). Conversely, it showed no significant toxicity to RAS/NF1 wild-type NB cells (IMR5) or normal tissue-derived cells up to 100 nM.
• Pathway Suppression: Treatment led to rapid, dose-dependent downregulation of p-ERK and p-S6 (mTORC1 readout), confirming on-target inhibition of the MAPK pathway.
• Apoptosis Induction: Treatment resulted in increased cleavage of PARP and Caspase 3. Crucially, RMC-6236 caused a dose-dependent upregulation of BIM (a pro-apoptotic protein) and BCL-2, while MCL-1 and BCL-xL remained stable.
• 3D Efficacy: RMC-6236 significantly reduced spheroid area in NB-EBc1 and SK-N-AS models at 1 nM and 10 nM concentrations.
• In Vivo Efficacy:
  • Tumor Growth: In both KRAS G12D and NRAS Q61K xenografts, RMC-6236 significantly attenuated tumor growth compared to vehicle controls. In the NRAS model, 6 of 8 tumors shrank.
  • Survival: All vehicle-treated mice reached tumor burden limits and were euthanized by day 40, whereas all RMC-6236-treated mice survived significantly longer.
  • Biomarkers: Excised tumors showed reduced Ki67 (proliferation) and reduced p-ERK/p-S6 levels.
• Synergy with Venetoclax:
  • RMC-6236 increased BIM:BCL-2 complexes.
  • Combining RMC-6236 with Venetoclax resulted in synergistic killing (Bliss synergy score > 0).
  • Venetoclax disrupted the BIM:BCL-2 complex, freeing BIM to induce apoptosis.
  • Validation: siRNA knockdown of BIM rescued cells from RMC-6236 and combination therapy-induced apoptosis, confirming BIM is the critical effector.

5. Significance

• Clinical Translation: The findings provide a strong rationale for advancing RMC-6236 into clinical trials for children with RAS-mutant or NF1-deficient high-risk neuroblastoma, a subgroup currently associated with dismal outcomes (28.6% 5-year event-free survival).
• Overcoming Resistance: RMC-6236 overcomes the limitations of MEK inhibitors (toxicity/resistance) and KRAS G12C inhibitors (mutation specificity) by targeting the active RAS state across all isoforms.
• Novel Combination Strategy: The study proposes a clinically relevant combination strategy (RMC-6236 + Venetoclax) that leverages the drug-induced upregulation of BIM to sensitize tumors to BCL-2 inhibition. Given Venetoclax's existing approval in hematologic malignancies and tolerability in pediatric trials, this combination offers a rapid path to clinical testing.
• Future Directions: The authors suggest expanding clinical testing to this specific subset of neuroblastoma patients, potentially improving survival rates for a population with few remaining therapeutic options.

Limitations Noted: The study was conducted in immunocompromised (NSG) mice, lacking an immune component, and utilized cell-line-derived xenografts (CDX) rather than patient-derived xenografts (PDX) due to a lack of available RAS-mutant PDX models.